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Background: Until recently, the removal of melanocytic nevi 
has been performed with a CO2 laser or Er:YAG laser. These 
lasers have been useful for removing affected spots. 
However, enlargement of spots or some sequelae, including 
depressed or hypertrophic scars, could develop as unwanted 
results. The Q-switched Nd:YAG laser has been used to 
remove deep-seated melanocytes, such as Ota nevus or 
tattoos. However, there have been no previous experiments 
performed to test the efficacy and safety of this laser treatment 
for melanocytic nevi. Objective: The objective of this study 
was to investigate the efficacy and safety of the 1,064 nm 
Q-switched Nd:YAG laser for removing melanocytic nevi, 
including congenital nevomelanocytic and acquired 
nevomelanocytic nevi. Methods: Two thousand and sixty 
four Korean patients with small melanocytic nevi were 
treated with a Q-switched Nd:YAG laser from 2005 to 2009. 
High-resolution photographs were taken in identical lighting 
and positions before and after the six weeks of treatment to 
observe the procedural efficacy. Results: About 70% of the 
nevi treated using a 1,064 nm Q-switched Nd:YAG laser 
were completely removed after one session. The other 30% 
were completely treated within three sessions. The 
appearance of sequelae such as hollow scars noticeably 
decreased compared to the results seen in CO2 or Er:YAG 
laser treatments. Conclusion: Use of the 1,064 nm Q- 
switched Nd:YAG laser is a safe and effective treatment 
modality for melanocytic nevi. (Ann Dermatol 24(2) 162∼
167, 2012)
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INTRODUCTION
Melanocytic nevi are very common and usually harmless. 
The vast majority require no treatment. However, some 
people may request nevi removal for cosmetic reasons, 
especially when they are located on exposed areas of the 
body such as the face, arms, hands and legs. Since the 
treatment of melanocytic nevi is often done for cosmetic 
reasons, it must not only be effective but also safe, and is 
performed so that the appearance of adverse sequelae is 
minimized as much as possible.
Melanocytic nevi are traditionally removed by surgical 
excision, cryotherapy or electrodessication. More recently, 
CO2 and Er:YAG laser therapies have been used due to 
their simple application and ability to treat multiple 
lesions in a short time. This advantage maximizes the 
optimal cosmetic results
1,2. However, the CO2 laser may 
cause post-operative scarring and pigmentary changes in 
the procedure site. Furthermore, the use of pigment- 
specific lasers, such as the Q-switched ruby laser and 
Q-switched alexandrite laser, may lead to an incomplete 
removal of nevus cells. 
The Q-switched Nd:YAG laser emits a longer, near- 
infrared ray of 1,064 nm that is capable of penetrating into 
the deeper regions of the skin. Therefore, it is able to 
destroy deep-seated dermal melanocytes by selective 
photothermolysis
3. For this reason, many dermatology 
clinics commonly use this laser to treat nevus of Ota and Efficacy and Safety of Q-switched Nd:YAG Laser for Nevi
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Fig. 1. (A) Melanocytic nevi before treatment. (B) Temporarily localized inhibition of blood flow by pulling the skin taut during the 
treatment. (C) Hemostasis by covering with tissue paper and applying tension in the vertical direction immediately after the laser
treatment. (D) Dressing with Tegasorb
Ⓡ (thin hydrocolloid band; 3M, North ryde, Sydney, Australia) right after laser treatment. (E) 
Results 7 days after laser treatment. (F) Results 14 days after laser treatment.
Hori, or to remove tattoos
4-6. Its effectiveness for dermal 
melanocytosis treatment has been demonstrated, but 
problems with bleeding have prevented this laser from 
being used for melanocytic nevi. Based on this infor-
mation, we postulated that control of bleeding can 
facilitate removal of melanocytic nevi with the Q-switched 
Nd:YAG laser, since nevi have a histology similar to the 
nevus of Ota and Hori. This study investigated this 
hypothesis.
MATERIALS AND METHODS
Patients
After a full explanation of the procedure and potential 
risks, informed consent was obtained from 2,064 healthy 
Korean patients with clinically benign melanocytic nevi 
between 2005 and 2009. The lesions were evenly 
pigmented, flat or just palpable and did not exceed 10 
mm in diameter. The color of the nevi varied from light Y J  K i m ,  e t  a l
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Table 2. Summary of the subjective improvement scoring from the blinded evaluation by two dermatologists
Excellent Good Fair Poor Total Excellent or
good cases (%)
Excellent
cases (%)
One treatment 821 618 407 218 2,064 69.7 39.8
Two treatments 726 278 218 21 1,243 80.8 58.4
Three treatments 419 46 50 2 517 89.9 81.0
Total 1,966 942 677 239 3,824 76.0 51.4
Table 1. Summary of the subjective improvement scoring by anatomical site
Excellent Good Fair Poor Total Excellent or
good cases (%)
Excellent
cases (%)
  Forehead 658 483 203 31 1,375 84.9 47.9
  Zygoma 432 351 476 34 1,293 60.6 33.4
  Cheek 1,002 614 265 11 1,892 85.4 53.0
  Nose 124 104 150 42 420 54.3 29.5
  Chin 387 257 386 24 1,054 61.1 36.7
brown to dark brown. Patients with small-sized congenital 
melanocytic nevi, acquired melanocytic nevi, blue nevi 
and spitz nevi were also enrolled, but individuals with a 
personal or family history of melanoma were excluded. 
Except for 28 men, all patients with melanocytic nevi 
were women. Patient age at the start of treatment ranged 
from 15 to 59 years. All patients had Fitzpatrick’s skin 
types III, IV and V.
Laser treatment 
EMLA
Ⓡ 5% cream (eutectic mixture of 2.5% lidocaine and 
2.5% prilocaine, AstraZeneca, Sodertalje, Stockholem, 
Sweden) was applied to the nevi 40 min before laser 
treatment (Fig. 1A). The areas were then cleaned with 
normal saline and eye shields were applied. All patients 
were treated with a single session of the Q-switched 
Nd:YAG laser (Medlite II, Conbio, Fremont, CA, USA). 
The lesions were irradiated at a wavelength of 1,064 nm 
and delivered over a spot 2 mm in diameter with a 
frequency of 10 Hz and power of 10 to 12 J. The laser 
shot was performed by shooting above the nevi while 
focusing and rapidly defocusing. Pulling the skin taunt 
temporarily blocked blood flow and inhibited bleeding 
during the treatment (Fig. 1B). Bleeding caused by the 
laser treatment was stanched with sterilized tissue paper, 
and tension was applied in the vertical direction for 
several minutes (Fig. 1C). Tissue papers were sterilized 
with a model EOG300 ethylene oxide gas sterilizer (Delta 
Medical, Ansan, Korea). To ensure consistency, all laser 
treatments were performed by the same physician who 
did not participate in the evaluation.
After treatment, the lesions were cleansed with normal 
saline and secondary skin (Tegasorb
Ⓡ, thin hydrocolloid 
band; 3M, North ryde, Sydney, Australia) was applied for 
two consecutive days (Fig. 1D). The dressing was changed 
every other day by each patient until complete re-epithe-
lialization occurred (Fig. 1E). The patients were also 
advised to avoid exposure to the sun and to use a broad- 
spectrum sunscreen. When some hyperpigmentation 
remained, the patients were able to undergo another 
session.
Evaluation
1) Anatomical site
The nevi on the faces of all the patients were removed. 
The face was further segmented into forehead, zygoma, 
cheek, nose and chin, which were evaluated after the final 
treatment. Even the case of multiple lesions was included 
for the evaluation.    
2) Clearance
All photographic documentation was performed using an 
identical camera (Nikon Coolpix 4500; Nikon, Tokyo, 
Japan) settings, lighting and patient positioning. Before 
each treatment and 6 weeks after the final session, photo-
graphic documentation was repeated. Two independent, 
experienced dermatologists performed objective clinical 
assessment of the pigmented lesions by separately com-
paring photographs taken before and after treatment. The 
mean data of the pigment clearance of each patient were 
classified into four categories: excellent clearance (＞80% 
cleared and does not need further treatment); good 
clearance (51∼80% cleared); moderate clearance (25∼
50% cleared); and poor (＜25% cleared). Photos were 
evaluated in blinded fashion (i.e., the photographs were Efficacy and Safety of Q-switched Nd:YAG Laser for Nevi
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Fig. 2. Results before (A) and after 
(B) the Q-switched Nd:YAG laser 
(Medlite II, Conbio, Fremont, CA, 
USA) treatment.
Fig. 3. Results before (A) and after 
(B) the Q-switched Nd:YAG laser 
(Medlite II, Conbio, Fremont, CA, 
USA) treatment.
randomly ordered and the examiners were unaware of 
whether the photographs were pre- or postoperative).
3) Patient satisfaction
Some patients completed a questionnaire to assess their 
subjective satisfaction with the laser treatment using a 
5-point grading system as follows: very satisfied, satisfied, 
somewhat satisfied, dissatisfied and very dissatisfied.
4) Side effects
Any possible complications and side effects (erythema, 
edema, texture changes, scarring, milia, postinflammatory 
hypopigmentation and hyperpigmentation) were recorded 
during post-operative follow-ups.
RESULTS
This study included 2,064 patients (2,036 women and 28 
men; aged 18 to 56 years; mean age, 28.3 years). The 
number of nevi per patient ranged from 1 to 23. All 
patients had Fitzpatrick’s skin types III, IV and V. Multiple 
nevi could be treated in a short time, and a single 
treatment for one nevus took approximately 2 to 4 
seconds.
Anatomical site
The treatment was conducted for the nevi on the faces of a 
total of 2,064 patients. The number of patients by section 
of face was as follows: forehead, n=1,375; zygoma, 
n=1,293; cheek, n=1,892; nose, n=420; and chin, 
n=1,054. The treatment effect was the highest for cheeks 
and the lowest for noses (Table 1).
Clearance
In 821 patients (39.8%), the nevi were completely 
removed with a single session of laser treatment and did 
not require additional sessions (Table 2). About 70% of 
the patients who underwent only one treatment received 
good-to-excellent results and, after more than two 
treatments, 90% of the patients received good-to-excellent 
results. Fig. 2 and 3 demonstrate the clinical results seen 
in the patients.
Patient satisfaction
A total of 1,302 patients (63%) returned the questionnaire 
assessing patient satisfaction with treatment results. The Y J  K i m ,  e t  a l
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Table 3. Patient satisfaction with the surgical outcomes
Patient's satisfaction level n (%)
  Satisfied 621 (47.7)
  Somewhat satisfied 487 (37.4)
  Very satisfied 158 (12.1)
  Dissatisfied  36 (2.8)
  Very dissatisfied   0
responses revealed that 621 (47.7%) patients were 
satisfied with their outcomes, 487 (37.4%) patients were 
somewhat satisfied and 158 (12.1%) patients were very 
satisfied (Table 3).
Side effects
In all patients, re-epithelization was completed between 7 
and 10 days. Redness persisted up to 2 weeks in all cases. 
No infection was observed postoperatively. Observed 
side-effects were a mild prickling sensation during treat-
ment and mild post-treatment erythema, both of which 
were resolved within a few hours. Treatment-induced 
pinpoint bleeding lasted 3 to 5 days, and swelling cleared 
in 2 to 4 days. Otherwise, noticeable major adverse 
effects such as atrophy, scars, hypopigmentation or 
hyperpigmentation were not observed.
DISCUSSION
The 1,064 nm Q-swithced Nd:YAG laser, a non-ablative 
and selective photothermolysis system, is commonly used 
in many dermatology clinics to treat various pigmentary 
disorders and for tattoo removal. In particular, therapeutic 
trials on post-inflammatory hyperpigmentation, melasma 
and acquired bilateral nevus of Ota-like macules have 
shown that this treatment approach is effective with 
minimal downtime and with no crust formation
7-9. The 
principal laser-skin interactions observed in dermal 
melanocytosis by Q-switched Nd:YAG laser treatment is 
based on photothermal and photomechanical interactions 
induced by selective photothermolysis
10. The 1,064 nm 
Q-switched Nd:YAG laser can cause dermal and epider-
mal melanosome rupture, melanosome rupture in mela-
nocytes and destruction of dermal melanophages
11,12. 
Anderson et al.
12 conducted a study examining selective 
photothermolysis of cutaneous pigmentation in guinea 
pigs using a Q-switched Nd:YAG laser with single-pulse 
exposures at 1,064, 532 and 355 nm that resulted in 
melanosome rupture within melanocytes and keratinocytes. 
In addition, Rosenbach et al.
13 reported the reduction of 
epidermal melanocytes and the number of functional and 
dermal melanocytic nests after treatment of benign acquired 
melanocytic nevi with Q-switched lasers. Therefore, we 
postulated that the Q-switched Nd:YAG laser could be an 
effective treatment modality to remove melanocytic nevi, 
which have histological features similar to dermal melano-
cytosis, as long as bleeding could be controlled.
To our knowledge, this is the first and largest study 
specifically investigating the efficacy and safety of the 
1,064 nm Q-switched Nd:YAG laser treatment for melano-
cytic nevi. In this study, 821 of 2,604 nevi (39.8%) were 
completely removed, and 1,439 of 2,064 nevi (69.7%) 
were almost cleared (excellent-to-good results) with a 
single session of laser treatment. Furthermore, 90% of the 
patients showed good-to-excellent results after two to 
three treatments without hyper- or hypopigmentation. This 
type of laser treatment is safe, brief and well-tolerated. 
Multiple lesions can be treated in a short time and 
postoperative care is minimal. Our data suggest that a 
single treatment is usually sufficient.
The safety of the Q-switched Nd:YAG laser is comparable 
to that of pigment-specific lasers in the treatment of 
melanocytic nevi. In our study, no apparent scarring was 
noted in any of the treated lesions. With a secondary skin 
dressing, wounds were re-epithelialized between 7 and 10 
days. Bleeding resulting from the procedure was minimal 
as it was easily controlled with sterilized tissue paper. 
Heavier bleeding was observed during treatment with the 
Nd:YAG laser compared to CO2 or Er:YAG lasers. How-
ever, our results indicate that less heat damage to the skin 
and appendages is essential for better skin regeneration, 
and the bleeding caused by laser treatment was actually 
helping re-epithelialization, leading to a reduction of 
recovery time and possibility of scarring.
Nevertheless, the treatment modality used in this study 
has some limitations. Noticeable improvements shown in 
the experiment only occurred with Medlite II laser equip-
ment, and some patients required additional treatment 
sessions to achieve a higher level of clinical improvement. 
In addition, as the present study has limitations associated 
with a retrospective and uncontrolled study, optimized 
prospective studies are required. The CO2 laser treatment 
could not be conducted for the same patient at the same 
time because a large-sized study had to be performed for 
cosmetic outpatients. Taking into account that the efficacy 
and safety of Q-switched Nd:YAG laser have yet to be 
reported, a prospective study for outpatients could not be 
conducted. However, this study provides clinical evidence 
that Q-switched Nd:YAG and CO2 laser show similar 
effects concerning the removal of nevi, which is expected 
to lay the foundation for a future study for comparing the 
CO2 laser and Q-switched Nd:YAG.   
In conclusion, 1,064 nm Q-switched Nd:YAG laser treat-Efficacy and Safety of Q-switched Nd:YAG Laser for Nevi
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ment of melanocytic nevi is comparable to other pigment- 
specific laser treatments based on speed, convenience, 
excellent cosmesis and the ease of repetition, if required. 
As previously noted, the present report lacks a histo-
pathological study and further investigations to address 
this should be performed. Nevertheless, the results clearly 
indicate that the 1,064 nm Q-switched Nd:YAG is an 
attractive option for treating melanocytic nevi at local 
dermatology clinics.
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